PDCD1 and T-cell non-Hodgkin lymphoma: Specifically, the attributable reasons for stopping anti–PD-1/PDL1 in the 17 patients included the following, namely, the treating physician's decision following radiologic progression alone (n = 12/17; 71%), for acute clinical deterioration combined with radiologic progression (n = 2/17; 12%), decision by the family to stop after radiologic progression (n = 2/17; 12%), and a second malignancy (T-cell lymphoma; n = 1).